About Illumigen
Illumigen is a company based in Osaka (Japan) founded in 2000 was acquired by Cubist Pharmaceuticals in December 2007. Illumigen has raised $956.85 thousand across 1 funding round from investors including Cubist Pharmaceuticals. Illumigen operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter Osaka, Japan
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$956.85 K (USD)
in 1 rounds
-
Latest Funding Round
$956.85 K (USD), Seed
Oct 29, 2007
- Investors
-
Employee Count
Not available
-
Acquired by
Cubist Pharmaceuticals
(Dec 24, 2007)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Illumigen
Illumigen has successfully raised a total of $956.85K through 1 strategic funding round. The most recent funding activity was a Seed round of $956.85 thousand completed in October 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Illumigen
Illumigen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cubist Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
|
Locked | Locked | Locked |
Investor details for Illumigen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Illumigen
Investment portfolio details for Illumigen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Illumigen
Detailed financials for Illumigen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Illumigen Comparisons
Peer comparison for Illumigen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Illumigen
Illumigen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Illumigen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Illumigen
Complete news archive for Illumigen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Illumigen
Illumigen was founded in 2000 and raised its 1st funding round 7 years after it was founded.
Illumigen is headquartered in Osaka, Japan. It is registered at Osaka, Osaka Prefecture, Japan.
Illumigen is a funded company, having raised a total of $956.85K across 1 funding round to date.
Illumigen was established in 2000 as a pharmaceutical company based in the United States. Focus was placed on developing treatments for infectious conditions, such as hepatitis C virus, respiratory syncytial virus, and related areas including obesity. Drug candidates were advanced through research and preclinical stages. Acquisition by Cubist Pharmaceuticals took place in December 2007, after which independent operations ceased.
Illumigen's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Illumigen has 1 investor. Key investors include Cubist Pharmaceuticals.